Novo Nordisk to pay up to EUR 1.165B ($1.3B) for Nanexa's long-acting injectable platform
Novo Nordisk is licensing Swedish biotech Nanexa's long-acting injectable technology for obesity and diabetes drugs, sending Nanexa shares up more than 100%.
AllSci · +13 outlets
FDA approves Merck's Welireg (belzutifan) plus Lenvima for previously treated advanced kidney cancer
The belzutifan-lenvatinib combination won approval for previously treated advanced clear cell renal cell carcinoma after cutting the risk of progression or deat
PharmExec.com · +6 outlets
FDA approves Eli Lilly's once-weekly insulin Onswik, escalating rivalry with Novo Nordisk
The weekly basal insulin could reduce injection frequency by more than 300 shots a year versus daily insulin, intensifying competition in the diabetes market.
Fierce Pharma · +6 outlets
FDA advisers vote in favor of Grail's Galleri multicancer blood test ahead of agency decision
The advisory panel's backing keeps Grail's $949 blood test on track for a possible FDA decision, though questions remain about its readiness for broad approval.
Fierce Biotech · +13 outlets
FDA expands Eli Lilly's Olumiant approval to children as young as 12 with severe alopecia areata
The expanded label makes Olumiant the first oral pill approved for severe immune-related hair loss in adolescents.
GuruFocus · +6 outlets
Eli Lilly partners with China's InnoCare in R&D pact worth up to $3.25B in milestones
Lilly will pay $100M upfront to start the collaboration, extending its strategy of sourcing early-stage drugs from China.
finance.biggo.com · +9 outlets
RNAi drug developer ADARx raises $446M in IPO
The listing adds a well-funded RNAi specialist to the public biotech market amid a broader rebound in sector financing.
BioPharma Dive · +4 outlets
TrumpRx drug pricing claims draw doubts from a new report
The report questions whether the platform delivers the world's lowest drug prices as claimed.
usatoday.com · +1 outlets
FDA grants priority review to durvalumab plus enfortumab vedotin in muscle-invasive bladder cancer
A priority review shortens the FDA's timeline for the combination in an earlier-line bladder cancer setting.
CancerNetwork · +7 outlets
Senate hearing: FDA commissioner nominee Overton parries vaccine questions
The confirmation hearing highlighted scrutiny over vaccine policy at the agency.
BioPharma Dive · +4 outlets
Novo Nordisk plans to cut 13,000 jobs to fund expansion
The restructuring comes as Novo warns Europe is losing pharma competitiveness.
Trak.in · +11 outlets
Acadia's Alzheimer's drug narrowly misses primary endpoint; higher dose favored on secondary measure
The miss weighed on Acadia shares, though a secondary signal at the higher dose may support further study.
Stock Titan · +2 outlets
Merck's experimental eye drug meets vision goal but shows higher eye bleeding rates than comparator
The mixed result complicates the competitive profile of Merck's ophthalmology candidate.
Stock Titan · +3 outlets
Prime Medicine receives FDA clearance for gene editing study
The clearance advances a genetic treatment aimed at a variant carried by roughly 100,000 people in the U.S.
benzinga.com · +14 outlets
Trump drug-pricing official advances to be RFK Jr.'s No. 2 at HHS
The move elevates a figure credited with negotiating drug-pricing deals into a senior HHS role.
washingtonexaminer.com · +14 outlets
Trump administration's second wave of drug pricing deals draws analysis
Legal and policy commentary assesses the second round of most-favored-nation style pricing agreements and projected savings.
JD Supra · +9 outlets
Mesoblast wins FDA approval for new Ryoncil potency assay
Every batch of Mesoblast's cell therapy will now face a potency check following approval.
Mugglehead Investment Magazine · +1 outlets
Viking Therapeutics shares soar after latest GLP-1 data
The data renewed investor interest in next-generation obesity drugs beyond injectables.
The Motley Fool